Literature DB >> 19531493

Endosomal endothelin-converting enzyme-1: a regulator of beta-arrestin-dependent ERK signaling.

Graeme S Cottrell1, Benjamin E Padilla, Silvia Amadesi, Daniel P Poole, Jane E Murphy, Markus Hardt, Dirk Roosterman, Martin Steinhoff, Nigel W Bunnett.   

Abstract

Neuropeptide signaling at the cell surface is regulated by metalloendopeptidases, which degrade peptides in the extracellular fluid, and beta-arrestins, which interact with G protein-coupled receptors (GPCRs) to mediate desensitization. beta-Arrestins also recruit GPCRs and mitogen-activated protein kinases to endosomes to allow internalized receptors to continue signaling, but the mechanisms regulating endosomal signaling are unknown. We report that endothelin-converting enzyme-1 (ECE-1) degrades substance P (SP) in early endosomes of epithelial cells and neurons to destabilize the endosomal mitogen-activated protein kinase signalosome and terminate signaling. ECE-1 inhibition caused endosomal retention of the SP neurokinin 1 receptor, beta-arrestins, and Src, resulting in markedly sustained ERK2 activation in the cytosol and nucleus, whereas ECE-1 overexpression attenuated ERK2 activation. ECE-1 inhibition also enhanced SP-induced expression and phosphorylation of the nuclear death receptor Nur77, resulting in cell death. Thus, endosomal ECE-1 attenuates ERK2-mediated SP signaling in the nucleus to prevent cell death. We propose that agonist availability in endosomes, here regulated by ECE-1, controls beta-arrestin-dependent signaling of endocytosed GPCRs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19531493      PMCID: PMC2755963          DOI: 10.1074/jbc.M109.026674

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation.

Authors:  Akira Tohgo; Kristen L Pierce; Eric W Choy; Robert J Lefkowitz; Louis M Luttrell
Journal:  J Biol Chem       Date:  2002-01-02       Impact factor: 5.157

2.  The distribution of P2X3 purine receptor subunits in the guinea pig enteric nervous system.

Authors:  Daniel P Poole; Patricia Castelucci; Heather L Robbins; Roberto Chiocchetti; John B Furness
Journal:  Auton Neurosci       Date:  2002-10-31       Impact factor: 3.145

3.  A mass spectrometry-based strategy for detecting and characterizing endogenous proteinase activities in complex biological samples.

Authors:  Sarah Robinson; Richard K Niles; H Ewa Witkowska; Kirsten J Rittenbach; Robert J Nichols; Jonathan A Sargent; Scott E Dixon; Akraporn Prakobphol; Steven C Hall; Susan J Fisher; Markus Hardt
Journal:  Proteomics       Date:  2008-02       Impact factor: 3.984

4.  The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex.

Authors:  K A DeFea; Z D Vaughn; E M O'Bryan; D Nishijima; O Déry; N W Bunnett
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

5.  Nuclear receptor and apoptosis initiator NGFI-B is a substrate for kinase ERK2.

Authors:  Hege H Slagsvold; Anne-Carine Østvold; Asa B Fallgren; Ragnhild E Paulsen
Journal:  Biochem Biophys Res Commun       Date:  2002-03-15       Impact factor: 3.575

6.  Substance P induced biosynthesis of the zinc finger transcription factor Egr-1 in human glioma cells requires activation of the epidermal growth factor receptor and of extracellular signal-regulated protein kinase.

Authors:  Alia Al-Sarraj; Gerald Thiel
Journal:  Neurosci Lett       Date:  2002-10-31       Impact factor: 3.046

7.  ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity.

Authors:  Ru-Rong Ji; Katia Befort; Gary J Brenner; Clifford J Woolf
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

8.  Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme.

Authors:  K Umekawa; H Hasegawa; Y Tsutsumi; K Sato; Y Matsumura; N Ohashi
Journal:  Jpn J Pharmacol       Date:  2000-09

9.  Endothelin-converting enzyme-1 degrades internalized somatostatin-14.

Authors:  Dirk Roosterman; Cordula Kempkes; Graeme S Cottrell; Benjamin E Padilla; Nigel W Bunnett; Christoph W Turck; Martin Steinhoff
Journal:  Endocrinology       Date:  2008-02-14       Impact factor: 4.736

10.  beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2.

Authors:  K A DeFea; J Zalevsky; M S Thoma; O Déry; R D Mullins; N W Bunnett
Journal:  J Cell Biol       Date:  2000-03-20       Impact factor: 10.539

View more
  36 in total

1.  Orthosteric, Allosteric and Biased Signalling at the Relaxin-3 Receptor RXFP3.

Authors:  Martina Kocan; Sheng Yu Ang; Roger J Summers
Journal:  Neurochem Res       Date:  2015-08-21       Impact factor: 3.996

Review 2.  Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.

Authors:  Martin S Steinhoff; Bengt von Mentzer; Pierangelo Geppetti; Charalabos Pothoulakis; Nigel W Bunnett
Journal:  Physiol Rev       Date:  2014-01       Impact factor: 37.312

Review 3.  Endosomes: a legitimate platform for the signaling train.

Authors:  Jane E Murphy; Benjamin E Padilla; Burcu Hasdemir; Graeme S Cottrell; Nigel W Bunnett
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-12       Impact factor: 11.205

4.  Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNS.

Authors:  Heather Vinet-Oliphant; Xavier Alvarez; Elizabeth Buza; Juan T Borda; Mahesh Mohan; Pyone P Aye; Florin Tuluc; Steven D Douglas; Andrew A Lackner
Journal:  Am J Pathol       Date:  2010-07-29       Impact factor: 4.307

Review 5.  Roles of proteolysis in regulation of GPCR function.

Authors:  G S Cottrell
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

6.  Neural peptidase endothelin-converting enzyme 1 regulates endothelin 1-induced pruritus.

Authors:  Makiko Kido-Nakahara; Jörg Buddenkotte; Cordula Kempkes; Akihiko Ikoma; Ferda Cevikbas; Tasuku Akiyama; Frank Nunes; Stephan Seeliger; Burcu Hasdemir; Christian Mess; Timo Buhl; Mathias Sulk; Frank-Ulrich Müller; Dieter Metze; Nigel W Bunnett; Aditi Bhargava; Earl Carstens; Masutaka Furue; Martin Steinhoff
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

Review 7.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

8.  Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief.

Authors:  Dane D Jensen; TinaMarie Lieu; Michelle L Halls; Nicholas A Veldhuis; Wendy L Imlach; Quynh N Mai; Daniel P Poole; Tim Quach; Luigi Aurelio; Joshua Conner; Carmen Klein Herenbrink; Nicholas Barlow; Jamie S Simpson; Martin J Scanlon; Bimbil Graham; Adam McCluskey; Phillip J Robinson; Virginie Escriou; Romina Nassini; Serena Materazzi; Pierangelo Geppetti; Gareth A Hicks; Macdonald J Christie; Christopher J H Porter; Meritxell Canals; Nigel W Bunnett
Journal:  Sci Transl Med       Date:  2017-05-31       Impact factor: 17.956

Review 9.  Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease.

Authors:  Javier Pacheco-Quinto; Aimee Herdt; Christopher B Eckman; Elizabeth A Eckman
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

10.  Endothelin-converting enzyme 2 differentially regulates opioid receptor activity.

Authors:  A Gupta; W Fujita; I Gomes; E Bobeck; L A Devi
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.